This 2021 review explores the therapeutic potential of combining NAD⁺ precursors, such as nicotinamide riboside (NR), with antioxidants like pterostilbene in treating amyotrophic lateral sclerosis (ALS). The study highlights how oxidative stress and disrupted NAD⁺ metabolism contribute to motor neuron degeneration in ALS. By enhancing NAD⁺ levels and activating pathways
